Brief: Jasper Therapeutics Announces First Patient Dosed In Phase 1B/2A Etesian Clinical Study
02/12/2024 22:23
Dec 2 (Reuters) - Jasper Therapeutics Inc JSPR.O :
* JASPER THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE
1B/2A
ETESIAN CLINICAL STUDY OF BRIQUILIMAB IN ASTHMA
* JASPER THERAPEUTICS INC - INITIAL DATA EXPECTED IN SECOND
HALF
OF 2025
Source text: ID:nGNX5SwZTF
Further company coverage: JSPR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jasper Therapeutics
See all newsBrief: Jasper Therapeutics Announces Commencement Of An Offer To Purchase Outstanding Warrants
Jasper Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Jasper Therapeutics Q2 loss per share beats estimates, raises $132 mln
Jasper Therapeutics, Inc. expected to post a loss of 35 cents a share - Earnings Preview
Jasper Therapeutics rises; co announces all-stock merger with Kira Pharma